Qiagen expands QIAstat-Dx syndromic testing menu

By LabPulse.com staff writers

January 10, 2022 -- Qiagen has expanded its QIAstat-Dx syndromic testing system menu and plans to launch a higher-throughput version of the system called QIAstat-Dx Rise later in 2022.

The new QIAstat-Dx menu now includes the ability to distinguish between gastrointestinal pathogens and between meningitis and encephalitis infections, the company said. The cartridges can be used to process one, four, or eight tests simultaneously, according to the firm.

Qiagen expects the higher-capacity QIAstat-Dx Rise testing system to launch in Europe in mid-2022 and in the U.S. at the end of the year. This version will be used with a new feature, QIAstat-Dx Smart Drawer, which automatically identifies sample types for QIAstat-Dx panels and allows for tracing and prioritization of digital cartridges.

Qiagen touts expanded uses for SARS-CoV-2, tuberculosis tests
Qiagen is touting new additions to the growing number of applications for its QIAcuity digital polymerase chain (PCR) reaction platform. The firm also...
Qiagen, DiaSorin partner on TB screening
The U.S. Food and Drug Administration has approved Qiagen's Liaison QuantiFeron-TB Gold Plus assay for use on DiaSorin's automated Liaison XS platform....
Qiagen and BD settle PCR patent lawsuit
Qiagen and Becton Dickinson (BD) have reached a settlement in a patent infringement lawsuit involving polymerase chain reaction (PCR) tests that Qiagen...
Qiagen launches new tuberculosis test
Qiagen has launched a new test to detect tuberculosis (TB) infection, which also received a CE Mark.
Qiagen reaches biological sample milestone
Qiagen's consumables kits have now been used to process more than 3 billion biological samples. Furthermore, the company's next-generation sequencing...

Copyright © 2022 LabPulse.com

Last Updated ls 1/10/2022 6:06:49 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current